Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072014 | 0.84 | MAPT (0.61) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL223464 | 0.83 | MAPT (0.62) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL3772532 | 0.79 | RORC (0.66) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL14721296 | 0.79 | MAPK1 (0.51) | MAPTKMT2ATP53PARP1 | |
| SCHEMBL13901736 | 0.78 | MAPT (0.59) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL10802219 | 0.77 | RORC (0.63) | MAPTSMN1; SMN2RORCNPC1RAB9A | |
| SCHEMBL222738 | 0.75 | PARP1 (0.82) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13901738 | 0.75 | APP (0.62) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL72371 | 0.73 | WNT3A (0.55) | PARP1PTPN1 | |
| SCHEMBL17532613 | 0.73 | TDO2 (0.51) | MAPTSMN1; SMN2MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | disclosed |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| EP-2307023-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009117659-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117659-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | MAPT 3595/4885SMN1; SMN2 4076/4885RORC 1418/4885 |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | MAPT 3595/4885SMN1; SMN2 4076/4885RORC 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.